CA2221684A1 - Nouvelle cathepsine et procedes et compositions d'inhibition de cathepsine - Google Patents

Nouvelle cathepsine et procedes et compositions d'inhibition de cathepsine Download PDF

Info

Publication number
CA2221684A1
CA2221684A1 CA002221684A CA2221684A CA2221684A1 CA 2221684 A1 CA2221684 A1 CA 2221684A1 CA 002221684 A CA002221684 A CA 002221684A CA 2221684 A CA2221684 A CA 2221684A CA 2221684 A1 CA2221684 A1 CA 2221684A1
Authority
CA
Canada
Prior art keywords
carbon atoms
cathepsin
group
compound
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002221684A
Other languages
English (en)
Inventor
Jay S. Tung
Sukanto Sinha
Lisa Mcconlogue
Gwen Tatsuno
John Anderson
Christopher M. F. Semko
Susanna Chrysler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Athena Neurosciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/469,362 external-priority patent/US5849711A/en
Priority claimed from US08/467,607 external-priority patent/US5783434A/en
Application filed by Individual filed Critical Individual
Publication of CA2221684A1 publication Critical patent/CA2221684A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des procédés d'inhibition de la sécrétion de peptide beta -amyloïde ( beta AP) par des cellules, lesquels procédés consistent à administrer aux cellules certains composés qui inhibent l'activité d'une protéase d'approximativement 31 kD impliquée dans la sécrétion de beta AP. Cette protéase de 31 kD a été désignée sous le nom de Cathepsine Y. Cette invention concerne également des procédés de criblage d'inhibiteurs de beta AP, qui consistent à déterminer l'activité de composés tests en présence de la Cathepsine Y et d'un substrat peptidique adéquat. Cette invention concerne enfin une séquence d'acide nucléique codant la Cathepsine Y, ainsi que l'expression et l'isolation de la Cathepsine Y.
CA002221684A 1995-06-06 1996-04-26 Nouvelle cathepsine et procedes et compositions d'inhibition de cathepsine Abandoned CA2221684A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/469,362 US5849711A (en) 1995-06-06 1995-06-06 Cathepsin and methods and compositions for inhibition thereof
US08/467,607 US5783434A (en) 1995-06-06 1995-06-06 Cathepsin and methods and compositions for inhibition thereof
US08/469,362 1995-06-06
US08/467,607 1995-06-06

Publications (1)

Publication Number Publication Date
CA2221684A1 true CA2221684A1 (fr) 1996-12-12

Family

ID=27042111

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002221684A Abandoned CA2221684A1 (fr) 1995-06-06 1996-04-26 Nouvelle cathepsine et procedes et compositions d'inhibition de cathepsine

Country Status (4)

Country Link
EP (1) EP0831920A4 (fr)
JP (1) JPH11506923A (fr)
CA (1) CA2221684A1 (fr)
WO (1) WO1996039194A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100490807B1 (ko) * 1995-11-28 2005-10-14 세파론, 인코포레이티드 시스테인및세린프로테아제의d-아미노산함유억제제
US5965614A (en) 1996-11-22 1999-10-12 Athena Neurosciences, Inc. N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
ATE296797T1 (de) * 1996-11-22 2005-06-15 Elan Pharm Inc N-(aryl/heteroaryl/alkylacetyl) amino saüre amide,pharmazeutische zusammensetzungen damit, und methodenzur inhibierung beta-amyloid peptid freisetzung oder synthese
US6642261B2 (en) 1997-11-21 2003-11-04 Athena Neurosciences, Inc. N-(aryl/heteroarylacety) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6191166B1 (en) 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6153652A (en) 1996-11-22 2000-11-28 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6211235B1 (en) 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6207710B1 (en) 1996-11-22 2001-03-27 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6117901A (en) 1996-11-22 2000-09-12 Athena Neurosciences, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
AR016751A1 (es) * 1996-11-22 2001-08-01 Athena Neurosciences Inc Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
DE19648793A1 (de) 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
AR011164A1 (es) * 1997-02-28 2000-08-02 Lilly Co Eli Compuestos heterociclicos, composiciones farmaceuticas que los comprenden, y metodos para inhibir la liberacion del peptido beta-amiloide y/o su sintesismediante el uso de dichos compuestos
WO1999031256A2 (fr) * 1997-12-18 1999-06-24 Immunex Corporation Proteines cathepsine dc, adn codant pour ces proteines et utilisation de ces proteines dans l'etablissement de pronostics pour les cancers chez l'homme
US6506782B1 (en) 1998-02-27 2003-01-14 Athena Neurosciences, Inc. Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
DE19818614A1 (de) * 1998-04-20 1999-10-21 Basf Ag Neue substituierte Amide, deren Herstellung und Anwendung
AU3818799A (en) * 1998-04-20 1999-11-08 Basf Aktiengesellschaft Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
AU6229699A (en) * 1998-10-26 2000-05-15 Sumitomo Pharmaceuticals Company, Limited Beta-amyloid formation inhibitors
ES2296834T3 (es) * 2002-02-14 2008-05-01 Biofrontera Pharmaceuticals Ag Inhibidores de la catepsina y para el desarrollo de un medicamento para el tratamiento del dolor.
WO2003079982A2 (fr) 2002-03-19 2003-10-02 Tularik Inc. Amplification de genes en cas de cancer
EP1347059A1 (fr) * 2002-03-20 2003-09-24 Biofrontera Pharmaceuticals AG Cathepsin Y, une cible pour le développment de médicaments pour le traitement d'accidents vasculaires cérébraux
WO2007054776A2 (fr) * 2005-11-10 2007-05-18 Orchid Research Laboratories Limited Composes semblables au stilbene comme inhibiteurs hdac atypiques

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221607A (en) * 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
IL97428A0 (en) * 1990-03-05 1992-06-21 Cephalon Inc Chymotrypsin-like proteases and their inhibitors
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5164295A (en) * 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
US5538845A (en) * 1992-02-05 1996-07-23 Athena Neurosciences, Inc. Beta-amyloid peptide production inhibitors and methods for their identification
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
WO1995013084A1 (fr) * 1992-05-11 1995-05-18 Miles Inc. Identification de la cathepsine d comme protease amyloïdogene de la maladie d'alzheimer
ZA936492B (en) * 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
CA2149892C (fr) * 1992-11-20 1998-12-08 Koji Kobayashi Inhibiteur et applications pharmaceutiques de cette substance
CZ184194A3 (en) * 1993-08-09 1995-03-15 Lilly Co Eli Aspartylprotease inhibitor and method of identifying thereof
PT721449E (pt) * 1993-10-01 2002-06-28 Merrell Pharma Inc Inibidores da producao da proteina beta-amiloide
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
WO1995031192A1 (fr) * 1994-05-16 1995-11-23 Thomas Jefferson University Methode et utilisation d'agents pour inhiber la polymerisation de proteines et methodes pour identifier ces agents
CA2152765A1 (fr) * 1994-06-30 1995-12-31 Jeroen Elisabeth-Joseph Knops Methodes pour traiter un trouble physiologique associe a un peptide amyloide beta
US5523295A (en) * 1994-07-06 1996-06-04 Brandeis University Method for treating and preventing alzheimer's disease
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US5849691A (en) * 1996-02-20 1998-12-15 The United States Of America As Represented By The Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II

Also Published As

Publication number Publication date
JPH11506923A (ja) 1999-06-22
EP0831920A1 (fr) 1998-04-01
WO1996039194A1 (fr) 1996-12-12
EP0831920A4 (fr) 2003-03-19

Similar Documents

Publication Publication Date Title
CA2221684A1 (fr) Nouvelle cathepsine et procedes et compositions d'inhibition de cathepsine
AU661270B2 (en) Chymotrypsin-like proteases and their inhibitors
CA2374346C (fr) Inhibiteurs de memapsine 2 et son utilisation
JP2537507B2 (ja) 組換え宿主から生産されたアプロチニン相同体、それらのための方法、発現ベクタ−および組換え宿主、およびそれらの製薬学的使用
CN102985439B9 (zh) Iap bir结构域结合化合物
US20030191054A1 (en) Novel bag proteins and nucleic acid molecules encoding them
US5849711A (en) Cathepsin and methods and compositions for inhibition thereof
AU2002239727C1 (en) Inhibitors of memapsin 2 and use thereof
KR101051249B1 (ko) 감마 세크레타제 저해제
JP2533869B2 (ja) Ｈｕｓｉ―ｉ型インヒビタ―の生物学的活性を有するタンパク質をコ―ドするｄｎａ配列、前記ｄｎａ配列を含む組換え体クロ―ニングベクタ―及び前記ベクタ―により形質転換された細菌
US5783434A (en) Cathepsin and methods and compositions for inhibition thereof
US5580955A (en) Fragments of neurofibromin (NF1) and method to reverse activated ras induced malignant transformation in mammalian cells
US5723301A (en) Method to screen compounds that affect GAPDH binding to polyglutamine
US6307035B1 (en) BRCA1 associated polynucleotide (BAP-1) and uses therefor
EP1496124A1 (fr) Inhibiteurs de mémapsine 2 et son utilisation
Giorgi et al. The Molecular Biology of Lithostathine (Pancreatic Stone Protein)
AU2004202058B2 (en) Inhibitors of memapsin 2 and use thereof
WO1999051742A2 (fr) Proteine activatrice de la mort du domaine de la mort (dadd)
AU2004202059A1 (en) Catalytically active recombinant memapsin and methods of use thereof

Legal Events

Date Code Title Description
FZDE Dead